Skip to content

Clinical trials

Observational Myocarditis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myocarditis Phase: Observational Clear all

110 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20042
20051
20061
20081
20091
20102
20111
20121
20131
20143
20151
20163
20172
20189
201910
202016
202112
202211
20238
20247
20258
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed36
Recruiting29
Unknown status26
Not yet recruiting10
Enrolling by invitation6
Active, not recruiting2
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris7
Groupe Hospitalier Pitie-Salpetriere5
Scientific Institute San Raffaele4
Assiut University3
Kansas City Heart Rhythm Research Foundation3
Mayo Clinic3
Medical University of Warsaw3
Chinese Academy of Medical Sciences, Fuwai Hospital2
First Affiliated Hospital Xi'an Jiaotong University2
German Heart Institute2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myocarditis110
Cardiomyopathies20
Heart Failure14
COVID-1913
Pericarditis13
Cardiovascular Diseases9
Myocardial Infarction9
Arrhythmias, Cardiac8
Cardiomyopathy, Dilated8
Cardiomyopathy, Hypertrophic8

Trials

Showing 26 to 50 of 110. Each trial links to its page on Pharma Observatory.

10 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.